Denosumab Biosimilar, N297A Mutant
$375.00
Denosumab Biosimilar, N297A Mutant. Denosumab biosimilar CHO stable cell line is available for licensing to manufacture the denosumab biosimilar protein.The research grade denosumab biosimilar protein is for research use only (RUO). Recombinant human IgG2 isotype controls are available.
- Product Details
- Description
- Additional information
- More Offers
| Catalog No. | C004P.NA |
|---|---|
| Product Name | Denosumab Biosimilar, N297A Mutant |
| Supplier Name | Syd Labs, Inc. |
| Brand Name | Syd Labs |
| Synonyms | Anti-RANKL Human Monoclonal Antibody |
| Summary | Recombinant Humanized IgG2 Monoclonal Antibody. |
| Isotype | Human IgG1 kappa |
| Source/Host | The monoclonal antibody denosumab biosimilar was produced in the denosumab biosimilar CHO stable cell line. |
| Specificity/Sensitivity | The monoclonal antibody denosumab biosimilar specifically binds to the human RANKL (RANK ligand) protein. |
| Form Of Antibody | 0.2 uM filtered solution, pH 5.2, no stabilizers or preservatives. |
| Endotoxin | < 1 EU per 1 mg of the protein by the LAL method. |
| Purity | >95% by SDS-PAGE under reducing conditions and HPLC. |
| Shipping | The Denosumab Biosimilar, N297A Mutant is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below. |
| Stability & Storage | Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 12 months from date of receipt, -20 to -70°C as supplied. 1 month from date of receipt, 2 to 8°C as supplied. |
| Note | Denosumab biosimilar CHO stable cell line is available for licensing to manufacture the denosumab biosimilar protein.The research grade denosumab biosimilar protein is for research use only (RUO). Recombinant human IgG2 isotype controls are available. |
| Order Offline | Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Orleave a message with a formal purchase order (PO) Or credit card. |
Description
C004P.NA: Denosumab Biosimilar, N297A Mutant
Recombinant Humanized IgG2 Monoclonal Antibody.
Background
Denosumab, a fully human monoclonal antibody, inhibits the RANKL (RANK ligand) protein, the primary signal for bone removal. Denosumab can be used for the treatment of osteoporosis, treatment-induced bone loss, bone metastases, multiple myeloma, and giant cell tumor of bone.
Syd Labs also provides the following research grade antibody biosimilar proteins:
Bevacizumab Biosimilar, research grade (VEGF-A)
Ranibizumab Biosimilar, research grade (VEGF-A, Fab produced in E. coli)
Cetuximab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Panitumumab Biosimilar, research grade (HER1, ErbB-1, EGFR)
Trastuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Pertuzumab Biosimilar, research grade (HER2, ErbB-2, c-neu)
Infliximab biosimilar, research grade (TNF alpha)
Adalimumab biosimilar, research grade (TNF alpha)
Rituximab biosimilar, research grade (CD20)
Denosumab biosimilar, research grade (RANKL, RANK ligand, OPGL, TNFSF11, CD254, TRANCE, ODF)
Palivizumab Biosimilar, research grade (RSV)
Omalizumab biosimilar, research grade (IgE)
Eculizumab biosimilar, research grade (C5)
Please remember our product information: Denosumab Biosimilar, N297A Mutant: C004P.NA Syd Labs
Additional information
| Ship from Country | USA |
|---|---|
| Size | 0.5 mg |